TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1233072
Drug: Salbutamol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (8 mg) administered twice daily as a sustained release formulation
Study: 1233072
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mug) administered by aerosol
Study: 31405750
Drug: N-acetylcysteine rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine rinse (10% solution, 2500 mg daily, 5 times daily during radiotherapy and 2 weeks post-radiotherapy)
Study: 23222413
Drug: Ginger (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (2.0 g/day)
Study: 18449063
Drug: Levofloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (10 mg/kg twice daily)
Study: 18449063
Drug: Amoxicillin/clavulanate (14:1;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (14:1; amoxicillin 45 mg/kg twice daily)
Study: 18449063
Drug: Levofloxacin and
Normalized name: levofloxacin and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin and Amoxicillin/clavulanate
Study: 10866907
Drug: ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.1 mg/kg IV injection
Study: 10866907
Drug: placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (normal saline) IV injection
Study: 10866907
Drug: diphenhydramine 30
Normalized name: pseudoephed/diphenhydramine 30 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphenhydramine 30 mg IV injection
Study: 9358912
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 25,000 IU vitamin A and 30 mg beta-carotene
Study: 8451310
Drug: 560 ml
Normalized name: ALCOHOL 392 mL in 560 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 ml of CMW
Study: 8451310
Drug: 560 ml
Normalized name: ALCOHOL 392 mL in 560 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 ml of APM-sweetened soft drink (340 mg APM)
Study: 8451310
Drug: 280 ml
Normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 ml of APM-sweetened mineral water (340 mg APM)
Study: 8451310
Drug: 280 ml
Normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 ml of carbonated mineral water (CMW)
Study: 8451310
Drug: 280 ml
Normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 ml of CMW with 340 mg of encapsulated APM
Study: 2870944
Drug: Pipothiazine palmitate
Normalized name: Pipothiazine palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipothiazine palmitate (PPT) 100 mg alternating with placebo
Study: 2870944
Drug: Flupenthixol decanoate
Normalized name: flupenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol decanoate (FPX) 40 mg
Study: 30440907
Drug: RAPAEL Smart
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAPAEL Smart Board therapy (30 minutes a day, 5 days per week, for 4 weeks) in addition to traditional treatments (30 minutes of functional arm movement therapy)
Study: 30440907
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (two 30-minute sessions, 5 days per week, for 4 weeks)
Study: 22806823
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg
Study: 21265123
Drug: Complex preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex preventive therapy including wobenzym
Study: 9469682
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol (HDL) 5 mg plus lorazepam (LZ) 2 mg (9 patients)
Study: 9469682
Drug: Intramuscular lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lorazepam (LZ) 2 mg (11 patients)
Study: 15730346
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg daily)
Study: 25616927
Drug: Bivalirudin (BIV-LOW)
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin (BIV-LOW) at 0.25 mg/kg/h
Study: 25616927
Drug: Bivalirudin (BIV-PCI)
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin (BIV-PCI) at 1.75 mg/kg/h
Study: 25616927
Drug: Heparin ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin ± GPI
Study: 23505929
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg oral dose administered 4 hours before the match)
Study: 23505929
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered to the control group)
Study: 21382864
Drug: Snoezelen room
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snoezelen room sessions (30 minutes, twice a week for six weeks)
Study: 19112801
Drug: Active gel
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gel (topical gel containing growth factors, cytokines, and soluble matrix proteins)
Study: 14653030
Drug: Therapeutic angiogenesis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic angiogenesis using recombinant growth-factor protein application or growth factor gene therapy.
Study: 14653030
Drug: Angiogenic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiogenic therapy (specifics not provided).
Study: 22515360
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Levofloxacin 500 mg once daily for 7 days
Study: 22515360
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Tetracycline 500 mg four times daily for 14 days
Study: 20513227
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release methylphenidate (MPH)
Study: 20513227
Drug: Twice-daily immediate-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily immediate-release methylphenidate (MPH)
Study: 16410734
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with diuretic indapamide and angiotensin-converting enzyme inhibitor perindopril if required
Study: 10685583
Drug: Ground-level oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground-level oxygen (GLO) treatment for 2 hours
Study: 9332329
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B 1 mg/kg/d (c‐AMB)
Study: 9332329
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 1 mg/kg/d (L‐AMB1)
Study: 9332329
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 3 mg/kg/d (L‐AMB3)
Study: 8229130
Drug: Discontinued exogenous
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued exogenous endocrine therapy
Study: 3094063
Drug: Ethanol (EtOH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol (EtOH) 0.33 ml/kg
Study: 3094063
Drug: Ethanol (EtOH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol (EtOH) 1.0 ml/kg
Study: 30903329
Drug: 800 ml
Normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 ml PEG + Asc (Regimen A)
Study: 30903329
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml PEG + Asc (Regimen B)
Study: 30903329
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml PEG + Asc (Regimen C)
Study: 21714641
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (CT) screening
Study: 15286133
Drug: Therapies directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies directed at correcting demineralization-remineralization imbalance
Study: 11217014
Drug: Zolpidem-induced sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem-induced sleep (10 mg)
Study: 8486328
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (SB) 250 mg
Study: 8486328
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (SB) 1,000 mg
Study: 24162462
Drug: Emulsified isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emulsified isoflurane (EI) at doses starting from 0.3 mg/kg to 64.6 mg/kg
Study: 20299628
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 500 microg bid + active theophylline capsules (plasma level of 8.8-12.4 mg/L)
Study: 20299628
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) alone
Study: 20299628
Drug: Placebo theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo theophylline capsules + inhaled placebo
Study: 20299628
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with FP and theophylline
Study: 16022206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no weekly messages)
Study: 1961958
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg (n = 40)
Study: 1961958
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg/kg (n = 40)
Study: 17224860
Drug: Isoflavone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone treatment
Study: 10980840
Drug: Direct thrombin
Normalized name: Direct thrombin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct thrombin inhibitors (hirudin, hirulog) as adjuncts to thrombolytic therapy
Study: 10980840
Drug: Hirudin administered
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin administered at a mean of 34 and 50 minutes after thrombolytic therapy
Study: 10980840
Drug: Direct thrombin
Normalized name: Direct thrombin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct thrombin inhibitors administered prior to thrombolysis
Study: 7594905
Drug: Ritodrine hydrochloride
Normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritodrine hydrochloride infusion
Study: 2183052
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with irradiation (27 Gy) of the involved field
Study: 28339738
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of TNF inhibitors (TNFi)
Study: 25588456
Drug: L-dopa (100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (100/25 mg of l-dopa/carbidopa daily)
Study: 19835117
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus acupoint injection (Group C)
Study: 19835117
Drug: Electroacupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture plus acupoint injection (Group D)
Study: 17919229
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and lamivudine combination therapy
Study: 17919229
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon monotherapy
Study: 17919229
Drug: Conventional interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional interferon monotherapy
Study: 17919229
Drug: Conventional interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional interferon and lamivudine combination therapy
Study: 7117677
Drug: Nabumetone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1 g at night)
Study: 371561
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg b.i.d.)
Study: 28877841
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy for health anxiety (CBT-HA) - 4 to 10 sessions of 1-hour CBT-HA
Study: 28877841
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy for health anxiety (CBT-HA)
Study: 11264066
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam spray (4 mg)
Study: 9681343
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% SDZ ASM 981 cream applied twice daily
Study: 9681343
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% SDZ ASM 981 cream applied once daily
Study: 25758624
Drug: 5% glucose-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose-containing intravenous solution (D5LR)
Study: 16485727
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) treatment (1200 mg/day in 3 divided doses for 3 days followed by 300 mg i.v. after anaesthesia induction)
Study: 16485727
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PTX treatment)
Study: 10866882
Drug: tranexamic acid,
Normalized name: Tranexamic Acid, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tranexamic acid, 10 mg. kg(‐1). h(‐1)
Study: 10866882
Drug: epsilon‐aminocaproic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: epsilon‐aminocaproic acid, 16 mg. kg(‐1). h(‐1)
Study: 3092780
Drug: Alprazolam treatment
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam treatment in 8 patients
Study: 24850615
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving weekly on-site lectures unrelated to exercise.
Study: 22219220
Drug: Surinabant 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surinabant 2.5 mg/day
Study: 22219220
Drug: Surinabant 5
Normalized name: Surinabant
DrugBank: Surinabant (DB13070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surinabant 5 mg/day
Study: 22219220
Drug: Surinabant 10
Normalized name: Surinabant
DrugBank: Surinabant (DB13070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surinabant 10 mg/day
Study: 18485010
Drug: Lower number
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower number of cells (10,000,000) in Group L, n = 13
Study: 18485010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cell treatment) in Group C, n = 17
Study: 15769986
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (30 mug ethinyl estradiol and 150 mug levonorgestrel) for 9 months
Study: 10406153
Drug: Defibrotide (800-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (800-1600 mg daily)
Study: 2210618
Drug: human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human growth hormone (hGH) alone
Study: 2210618
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy with oxandrolone
Study: 6108555
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg i.v.
Study: 6108555
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg i.v.
Study: 20638139
Drug: Lip strengthening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lip strengthening exercises using an oral screen for 16 min, 5 days/week for 16 weeks.
Study: 20638139
Drug: Lip strengthening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lip strengthening exercises using an oral screen.
Study: 15508179
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with birch pollen extract
Study: 17012870
Drug: Hexavalent combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent combined vaccine (DTaP‐IPV‐PRP approximately T‐HBs, HEXAVAC)
Study: 18447898
Drug: Static night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static night splinting for six months worn at night time only, in addition to hand therapy.
Study: 18447898
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy only (non-splint group).
Study: 12593525
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) 800 microg day(‐1) suspension for nebulization
Study: 10414911
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and GM-CSF
Study: 31353989
Drug: nalbuphine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.07 mg/kg
Study: 31353989
Drug: dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 0.5 µg/kg
Study: 29079057
Drug: Cold saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold saline irrigation (20 mL at 2.5°C for 5 minutes)
Study: 1444945
Drug: EMLA 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 5% Cream
Study: 22876438
Drug: Weifuchun tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weifuchun tablets
Study: 20398351
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 gram by intravenous injection)
Study: 18548827
Drug: Mirtazapine 7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 7.5, 15, 30, and/or 45 mg (Study 1)
Study: 18548827
Drug: Mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15 mg (Study 2)
Study: 18548827
Drug: Mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15 mg + Compound CD0012 (Study 2)
Study: 16217274
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors and 4-hydroxytamoxifen
Study: 10378706
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg daily)
Study: 7712685
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg daily)
Study: 6316518
Drug: Biostim (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostim (8 mg/day) for 15 days
Study: 30971316
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of special medication (IV fluid, IV antibiotic, and blood transfusion)
Study: 22243494
Drug: Warfarin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin + Anacetrapib
Study: 19640014
Drug: Schema-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema-Focused Therapy (SFT)
Study: 3988972
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg/kg
Study: 15815895
Drug: Cisatracurium infusion
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium infusion
Study: 12444178
Drug: HPV‐16 virus‐like‐particle
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐16 virus‐like‐particle vaccine (40 microg per dose)
Study: 10349300
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of ethylcysteine (EC) for 3 months
Study: 10349300
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of Vitamin E (Vit. E) for 3 months
Study: 7173046
Drug: Codeine sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine sulfate 60 mg po
Study: 7173046
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 60 mg im
Study: 29399865
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU cholecalciferol daily for 5 months
Study: 8225149
Drug: Moxonidine (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.2-0.4 mg daily)
Study: 23881862
Drug: 60-second-delayed therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-second-delayed therapy (arm C)